html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 17 Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson’s disease Malco Rossi, Daniel Cerquetti, Jorge Mandolesi and Marcelo Merello Introduction Surgery for movement disorders,…
Figure 15.1 Summary flowchart for the treatment of sleep disorders in Parkinson’s disease resulting from evidence-based data. Levels of recommendation are based on the American Academy of Neurology practice parameters…
Figure 7.1 Levodopa plasma concentrations with standard oral therapy, for a patient taking five daily doses of levodopa/carbidopa perorally (100+100+75+75+100mg every second hour). Graph published with permission from Dag Nyholm….
Figure 14.1 Outline of dopamine replacement therapy. Reprinted with permission, Cleveland Clinic Center for Medical Art and Photography, 2014. All Rights Reserved. Unfamiliarity with the delicate nuances of DRT can…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 13 Management of disease-related behavioral disturbances in Parkinson’s disease Joseph H. Friedman Introduction Although categorized as a movement disorder, Parkinson’s disease (PD) is a neurobehavioral…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 12 A neurobehavioralist approach to the management of cognitive impairment in Parkinson’s disease Po-Heng Tsai Introduction Parkinson’s disease (PD) is traditionally characterized by its motor…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 10 Management of autonomic dysfunction in Parkinson’s disease Shen-Yang Lim and Ai Huey Tan Introduction Autonomic dysfunction can occur many years before a diagnosis of…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 11 Management of cognitive impairment in Parkinson’s disease Dawn M. Schiehser, Eva Pirogovsky-Turk and Irene Litvan Background on cognitive impairment in Parkinson’s disease Cognitive impairment…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 9 Experimental pharmacological agents in the management of Parkinson’s disease Krishe Menezes, Lawrence W. Elmer and Robert A. Hauser Introduction On the contrary, there appears…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 8 Catechol-O-methyltransferase inhibitors in the management of Parkinson’s disease Ilana Schlesinger and Amos D. Korczyn The introduction of 3,4-dihydroxyphenylalanine (DOPA) to the treatment of Parkinson’s…
